An overwhelming volume of arbitration requests has made it difficult for providers, including labs, to quickly challenge and resolve payment disputes under the law.
Sherlock Biosciences to Acquire Sense Biodetection
The firms intend to combine Sherlock's CRISPR technology and Sense's rapid molecular amplification chemistries, accelerating Sherlock's go-to-market strategy.
Ampel will use the signature to develop FibroGene, a fibromyalgia blood test that the company expects to launch next year.
Launched in Europe in 2018 and the US in 2020, the fully automated mass spec-based analyzer failed to gain market traction, in large part due to a limited assay menu.
The Boston-based company has developed a loop-mediated amplification assay and a novel lateral flow strip technology.
Biosynex to Acquire Chembio Diagnostics for $17.2M
Biosynex will buy all of Chembio's shares at $.45 per share in an all-cash deal that merges two developers and makers of point-of-care diagnostic tests.
The technology uses DNA nanostructures paired with nanopore sensing to potentially detect hundreds of targets per sample.